Shield Therapeutics PLC's (LON:STX) Dr Mark Sampson speaks to Proactive London's Andrew Scott ahead of them presenting positive data from the Phase 3b, open-label randomised controlled trial of Feraccru.
He says the trial shows the drug, also known as Accrufer in the States, offers a real oral alternative to intravenous iron for patients with iron deficiency anaemia.
